|
1
|
Chen G, Li S, Lu J, Liang A, Gao P, Ou F,
Wang Y, Li Y and Pan B: LncRNA ZFHX4-AS1 as a novel biomarker in
adrenocortical carcinoma. Transl Androl Urol. 13:1188–1205. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu W, Li A, He H, Ye S, Zhou Z, Quan JH
and Tan W: Long noncoding RNA LINC01550 inhibits colorectal cancer
malignancy by suppressing the Wnt/β-catenin signaling pathway. J
Biochem Mol Toxicol. 38:e237742024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma H, Weng F, Tong X, Li H, Yao Y and Yuan
J: LncRNA TRPM2-AS promotes endometrial carcinoma progression and
angiogenesis via targeting miR-497-5p/SPP1 axis. Cell Mol Biol
Lett. 29:932024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang J, Shi J, Xiang Y, Wang ZW, Qi FF, Li
ZY, Zhao LL, Zhu GH, Duan YY, Yang ZY, et al: LINC00525 enhances
ZNF460-regulated CD24 expression through the sponge miR-125a-5p to
promote malignant progression of breast cancer. J Cancer Res Clin
Oncol. 150:3172024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li D, Liu X, Jiang N, Ke D, Guo Q, Zhai K,
Han H, Xiao X and Fan T: Interfering with ITGB1-DT expression
delays cancer progression and promotes cell sensitivity of NSCLC to
cisplatin by inhibiting the MAPK/ERK pathway. Am J Cancer Res.
12:2966–2988. 2022.PubMed/NCBI
|
|
6
|
Liu N, Zhang C and Zhang L: WTAP-involved
the m6A modification of lncRNA FAM83H-AS1 accelerates the
development of gastric cancer. Mol Biotechnol. 66:1883–1893. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Da J, Liu P, Wang R and Bu L: Upregulation
of the long non-coding RNA FAM83H-AS1 in gastric cancer and its
clinical significance. Pathol Res Pract. 215:1526162019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Guan G and Zhao D: Silence of
FAM83H-AS1 promotes chemosensitivity of gastric cancer through
Wnt/β-catenin signaling pathway. Biomed Pharmacother.
125:1099612020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu B, Gao W, Sun W, Li L, Wang C, Yang X,
Liu J and Guo Y: Promoting roles of long non-coding RNA FAM83H-AS1
in bladder cancer growth, metastasis, and angiogenesis through the
c-Myc-mediated ULK3 upregulation. Cell Cycle. 19:3546–3562. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shan H, Yang Y, Zhu X, Han X, Zhang P and
Zhang X: FAM83H-AS1 is associated with clinical progression and
modulates cell proliferation, migration, and invasion in bladder
cancer. J Cell Biochem. 120:4687–4693. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma YK, Shen TH and Yang XY: Upregulation
of LncRNA FAM83H-AS1 in hepatocellular carcinoma promotes cell
proliferation, migration and invasion by Wnt/β-catenin pathway. Eur
Rev Med Pharmacol Sci. 23:7855–7862. 2019.PubMed/NCBI
|
|
12
|
Wang R, Yu X, Ye H, Ao M, Xi M and Hou M:
LncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by
promoting DNMT1-mediated CDO1 promoter hypermethylation. J Biol
Chem. 300:1076802024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barr JA, Hayes KE, Brownmiller T, Harold
AD, Jagannathan R, Lockman PR, Khan S and Martinez I: Long
non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16
E6 independently of p53 in cervical cancer cells. Sci Rep.
9:36622019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo XJ, Lu YX, Wang Y, Huang R, Liu J, Jin
Y, Liu ZK, Liu ZX, Huang QT, Pu HY, et al: M6A-modified lncRNA
FAM83H-AS1 promotes colorectal cancer progression through PTBP1.
Cancer Lett. 598:2170852024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang L, Cui J, Wang Y and Tan J:
FAM83H-AS1 is upregulated and predicts poor prognosis in colon
cancer. Biomed Pharmacother. 118:1093422019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu S, Dong W, Zhao P and Liu Z: lncRNA
FAM83H-AS1 is associated with the prognosis of colorectal carcinoma
and promotes cell proliferation by targeting the Notch signaling
pathway. Oncol Lett. 15:1861–1868. 2018.PubMed/NCBI
|
|
17
|
Yang L, Xu L, Wang Q, Wang M and An G:
Dysregulation of long non-coding RNA profiles in human colorectal
cancer and its association with overall survival. Oncol Lett.
12:4068–4074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou M, Pan S, Qin T, Zhao C, Yin T, Gao
Y, Liu Y, Zhang Z, Shi Y, Bai Y, et al: LncRNA FAM83H-AS1 promotes
the malignant progression of pancreatic ductal adenocarcinoma by
stabilizing FAM83H mRNA to protect β-catenin from degradation. J
Exp Clin Cancer Res. 41:2882022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ríos-Romero M, Cedro-Tanda A, Peña-Luna M,
Mancera-Rodríguez MA, Hidalgo-Pérez L, Cisneros-Villanueva M,
Beltrán-Anaya FO, Arellano-Llamas R, Jiménez-Morales S, Alfaro-Ruíz
LA, et al: FAM83H-AS1 is a potential modulator of cancer driver
genes across different tumors and a prognostic marker for ER/PR +
BRCA patients. Sci Rep. 10:141452020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
El-Ashmawy NE, Hussien FZ, El-Feky OA,
Hamouda SM and Al-Ashmawy GM: Serum LncRNA-ATB and FAM83H-AS1 as
diagnostic/prognostic non-invasive biomarkers for breast cancer.
Life Sci. 259:1181932020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qian D, Qian C, Ye B, Xu M, Wu D, Li J, Li
D, Yu B and Tao Y: Development and validation of a novel
stemness-index-related long noncoding RNA signature for breast
cancer based on weighted gene co-expression network analysis. Front
Genet. 13:7605142022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deva Magendhra Rao AK, Patel K, Korivi
Jyothiraj S, Meenakumari B, Sundersingh S, Sridevi V, Rajkumar T,
Pandey A, Chatterjee A, Gowda H and Mani S: Identification of
lncRNAs associated with early-stage breast cancer and their
prognostic implications. Mol Oncol. 13:1342–1355. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han C, Fu Y, Zeng N, Yin J and Li Q:
LncRNA FAM83H-AS1 promotes triple-negative breast cancer
progression by regulating the miR-136-5p/metadherin axis. Aging
(Albany NY). 12:3594–3616. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang F, Lv SX, Lv L, Liu YH, Dong SY, Yao
ZH, Dai XX, Zhang XH and Wang OC: Identification of lncRNA
FAM83H-AS1 as a novel prognostic marker in luminal subtype breast
cancer. Onco Targets Ther. 9:7039–7045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Yu Y, Cao X and Chen P: Role of
lncRNA FAM83H antisense RNA1 (FAM83H-AS1) in the progression of
non-small cell lung cancer by regulating the miR-545-3p/heparan
sulfate 6-O-sulfotransferase (HS6ST2) axis. Bioengineered.
13:6476–6489. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang S, Han C, Liu T, Ma Z, Qiu M, Wang J,
You Q, Zheng X, Xu W, Xia W, et al: FAM83H-AS1 is a noncoding
oncogenic driver and therapeutic target of lung adenocarcinoma.
Clin Transl Med. 11:e3162021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Feng S, Su W, Bai S, Xiao L, Wang
L, Thomas DG, Lin J, Reddy RM, Carrott PW, et al: Overexpression of
FAM83H-AS1 indicates poor patient survival and knockdown impairs
cell proliferation and invasion via MET/EGFR signaling in lung
cancer. Sci Rep. 7:428192017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong YB and Zou YF: Clinical significance
of lncRNA FAM83H-AS1 in ovarian cancer. Eur Rev Med Pharmacol Sci.
23:4656–4662. 2019.PubMed/NCBI
|
|
29
|
Yuan X, Huang Y, Guo M, Hu X and Li P:
Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver
in human ovarian cancer. J Ovarian Res. 14:62021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dou Q, Xu Y, Zhu Y, Hu Y, Yan Y and Yan H:
LncRNA FAM83H-AS1 contributes to the radioresistance,
proliferation, and metastasis in ovarian cancer through stabilizing
HuR protein. Eur J Pharmacol. 852:134–141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu B, Qian D, Zhou W, Jiang H, Xiang Z
and Wu D: A novel androgen-induced lncRNA FAM83H-AS1 promotes
prostate cancer progression via the miR-15a/CCNE2 axis. Front
Oncol. 10:6203062021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bi YY, Shen G, Quan Y, Jiang W and Xu F:
Long noncoding RNA FAM83H-AS1 exerts an oncogenic role in glioma
through epigenetically silencing CDKN1A (p21). J Cell Physiol.
233:8896–8907. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bu L, Wang R, Liu P and Da J: Aberrantly
upregulated FAM83H-AS1 facilitates malignant progression of
esophageal squamous cell carcinoma. Oncol Lett. 20:3682020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng B, Wang G, Liang X, Wu Z, Wang X,
Dong Z, Guo Y, Shen S, Liang J and Guo W: LncRNA FAM83H-AS1
promotes oesophageal squamous cell carcinoma progression via
miR-10a-5p/Girdin axis. J Cell Mol Med. 24:8962–8976. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
El-Ashmawy NE, Al-Ashmawy GM and Hamouda
SM: Long non-coding RNA FAM83H-AS1 as an emerging marker for
diagnosis, prognosis and therapeutic targeting of cancer. Cell
Biochem Funct. 39:350–356. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li D, Li K, Zhang W, Yang KW, Mu DA, Jiang
GJ, Shi RS and Ke D: The m6A/m5C/m1A regulated gene signature
predicts the prognosis and correlates with the immune status of
hepatocellular carcinoma. Front Immunol. 13:9181402022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang X, Liu B, Nie Z, Duan L, Xiong Q,
Jin Z, Yang C and Chen Y: The role of m6A modification in the
biological functions and diseases. Signal Transduct Target Ther.
6:742021. View Article : Google Scholar : PubMed/NCBI
|
